UroGen Pharma (URGN) Cash from Investing Activities (2018 - 2026)

UroGen Pharma's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$20.7 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 20.32% year-over-year to -$20.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.8 million (up 211.21% YoY) and the FY2025 annual result came in at $61.6 million, up 398.64% from the prior year.
• Cash from Investing Activities was -$20.7 million for Q1 2026 at UroGen Pharma, down from $27.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $60.6 million in Q4 2024 and bottomed at -$106.8 million in Q3 2024.
• A 5-year average of $1.2 million and a median of $6.3 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 2563.58% — and 2024, when it sank 26720.95%.
• UroGen Pharma's Cash from Investing Activities stood at $23.1 million in 2022, then slumped by 149.09% to -$11.3 million in 2023, then soared by 634.39% to $60.6 million in 2024, then slumped by 54.28% to $27.7 million in 2025, then sank by 174.64% to -$20.7 million in 2026.
• Business Quant data shows URGN's Cash from Investing Activities at -$20.7 million in Q1 2026, $27.7 million in Q4 2025, and $31.4 million in Q3 2025.